EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 680 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL September 21, 2021 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 Pharmacy services are an untapped resource in tackling nation’s major health... July 12, 2022 Five Questions With…Desiree. April 21, 2022 Load more HOT NEWS Cancer in My Community: Working to Eliminate the Stigma of Cancer... A New FDA Approval Furthers the Role of Genomics in Cancer... HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial...
